New drug combo shows promise against resistant ovarian cancer
NCT ID NCT04374630
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This Phase 2 trial tested whether adding afuresertib (an AKT inhibitor) to standard paclitaxel chemotherapy helps control platinum-resistant ovarian cancer better than paclitaxel alone. 150 women with this difficult-to-treat cancer participated. The study measured how long the cancer stayed under control and overall survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Afuresertib (an AKT inhibitor) plus paclitaxel chemotherapy
What this could lead to
If successful, this combination could offer a new treatment option to slow cancer progression in patients with platinum-resistant ovarian cancer.
What could go wrong
This is a Phase 2 trial with only 150 participants, so results may not confirm effectiveness. Side effects from the drug combination are possible and need further study.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY PERITONEAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Abington Memorial Hospital
Willow Grove, Pennsylvania, 19090, United States
-
Arizona Oncology
Tucson, Arizona, 85711, United States
-
Arizona Oncology Associates
Phoenix, Arizona, 85016, United States
-
Baylor Scott & White Medical Center
Temple, Texas, 76508, United States
-
Beijing Obstetrics & Gynecology Hospital, Capital Medical University
Beijing, China
-
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, China
-
Chongqing University Cancer Hospital
Chongqing, China
-
Gynecology Oncology Associates Newport Beach
Newport Beach, California, 92663, United States
-
Harbin Medical University Cancer Hospital
Heilongjiang, China
-
Henan Cancer Hospital
Henan, China
-
Highlands Oncology Group
Rogers, Arkansas, 72758, United States
-
Holy Name Medical Center
Teaneck, New Jersey, 07666, United States
-
Houston Methodist Hospital
Houston, Texas, 77030, United States
-
Hubei Cancer Hospital
Hubei, China
-
Hunan Cancer Hospital
Hunan, China
-
Jilin Cancer Hospital
Jilin City, China
-
Kapiolani Medical Center for Women and Children
Honolulu, Hawaii, 96826, United States
-
Liaoning Cancer Hospital
Liaoyang, China
-
MD Anderson Cancer Center at Cooper
Camden, New Jersey, 08103, United States
-
Montefiore Medical Center
The Bronx, New York, 10467, United States
-
Nebraska Methodist Hospital
Omaha, Nebraska, 68114, United States
-
OHCare Oncology Hematology Care (OHC), Inc. - Kenwood Office
Cincinnati, Ohio, 45242, United States
-
Obstetrics & Gynecology Hospital of Fudan University
Shanghai, China
-
Peking University Cancer Hospital
Beijing, China
-
Qilu Hospital of Shandong University
Shandong, China
-
Rocky Mountain Cancer Centers
Littleton, Colorado, 80120, United States
-
Southwest Women's Oncology Group
Albuquerque, New Mexico, 87106, United States
-
Sun Yat-sen University Cancer Center
Guangdong, China
-
Texas Oncology
Austin, Texas, 78731, United States
-
Texas Oncology
Fort Worth, Texas, 76104, United States
-
Texas Oncology
The Woodlands, Texas, 77380, United States
-
The Second Hospital of Tianjin Medical University
Tianjin, China
-
Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States
-
Tufts Medical Center
Boston, Massachusetts, 02111, United States
-
US Texas Oncology
San Antonio, Texas, 78240, United States
-
USO Texas Oncology
Longview, Texas, 75601, United States
-
University of Chicago
Chicago, Illinois, 60637, United States
-
University of Cincinnati Medical Center
Cincinnati, Ohio, 45219, United States
-
University of Massachusetts
Worcester, Massachusetts, 01605, United States
-
University of Texas Health Science Center at Houston
Houston, Texas, 77030, United States
-
University of Washington/Seattle Cancer Care Alliance
Seattle, Washington, 98109, United States
-
Virginia Oncology Associates
Norfolk, Virginia, 23502, United States
-
West China Second University Hospital,Sichuan University
Sichuan, China
-
Women & Infants Hospital of Rhode Island
Providence, Rhode Island, 02905, United States
-
Women's Cancer Care
Covington, Louisiana, 70433, United States
-
Women's Hospital school of medicine Zhejiang University
Zhejiang, China
-
Zhongshan Hospital affiliated to Fudan University
Shanghai, China